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A B S T R A C T
With almost 2 million new HIV infections worldwide each year, the prevention of HIV infection is critical for
stopping the pandemic. The only approved form of pre-exposure prophylaxis is a costly daily pill, and it is
recognized that several options will be needed to provide protection to the various affected communities around
the world. In particular, many at-risk people would benefit from a prevention method that is simple to use and
does not require medical intervention or a strict daily regimen. We show that silk fibroin protein can be for-
mulated into insertable discs that encapsulate either an antibody (IgG) or the potent HIV inhibitor 5P12-
RANTES. Several formulations were studied, including silk layering, water vapor annealing and methanol
treatment to stabilize the protein cargo and impact the release kinetics over weeks. In the case of IgG, high
concentrations were released over a short time using methanol treatment, with more sustained results with the
use of water vapor annealing and layering during device fabrication. For 5P12-RANTES, sustained release was
obtained for 31 days using water vapor annealing. Further, we show that the released inhibitor 5P12-RANTES
was functional both in vitro and in ex vivo colorectal tissue. This work shows that silk fibroin discs can be
developed into formidable tools to prevent HIV infection.
1. Introduction
Currently there are almost 2 million new HIV infections worldwide
per year, a number that remains stubbornly high due to limited pre-
vention methods even as treatment options continue to expand. Several
populations are at particularly high risk: in the developed world, men
who have sex with men (MSM) are disproportionately affected; while in
the developing world, young women are among the most vulnerable
[1–3]. Indeed, worldwide, heterosexual women comprise the majority
of adults living with HIV. Recent clinical trial results have revealed a
particularly troubling trend, showing that even efficacious prevention
methods are not adopted by young women and adolescents (25 years
old and below), while their older peers show better compliance and
attain some level of protection. For example, the VOICE (Vaginal and
Oral Interventions to Control the Epidemic) trials included over 5000
women and utilized oral prophylaxis (daily pills) as well as gel inserts.
In these studies, low user compliance among young women led to a
nearly 10% HIV infection rate at some sites for that group [4]. More
recently, the vaginally inserted dapivirine ring has shown some success
but requires user compliance for effectiveness and was found to not be
effective for users under the age of 21 [5]. Overall, while these methods
and current trials with intravenous/injectable antibodies [6] are all
likely to provide good protection, the issue remains that user com-
pliance is a key, often overlooked, factor in HIV prevention, particularly
among adolescents. Therefore, a critical task in reducing new HIV in-
fections is to provide alternatives that are attractive to the user so that
they will be properly utilized.
HIV microbicides are generally envisioned as topically adminis-
tered, user-controlled antiviral agents such as insertable gels or films.
Ideally, these would not need refrigeration and could be obtained in-
expensively off-the-shelf in the developing world for use as needed. Due
to the low cost and lack of need for advanced planning or medical
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intervention, microbicides can fill an important niche in the fight
against HIV. However, as mentioned, low compliance with gels and
other modalities has led to the need for options that are more attractive
to users. As such, a microbicide that is capable of providing sustained
release over the course of days or weeks would be a critical tool for use
by vulnerable populations that are unwilling or unable to comply with
strict dosing schedules for protection.
Silk fibroin (hereinafter referred to as silk) is a natural protein de-
rived from the silk cocoons of Bombyx mori silkworms, and has been
shown to be biocompatible, biodegradable, non-inflammatory, and
extremely versatile in its applications as it can be formed into nano/
microparticles, microneedles, hydrogels, sponges, fibers, films, discs
and tubes [7]. Silk fibroin, the core protein used in this work, does not
cause an immune response or a significant inflammatory reaction as
demonstrated in many publications over the past 20 years, as well as
based on the FDA approval for silk-based medical devices. Thus, it can
be safely applied via vaginal or rectal routes [8,9]. In addition to being
a Food and Drug Administration (FDA) approved biomaterial as med-
ical sutures and soft tissue scaffolds [10], silk has shown the ability to
successfully deliver a wide range of bioactive molecules including an-
tineoplastic drugs [11–18], antibiotics [19], antiepileptics [20], genes
[21,22] and biological drugs such as growth factors [23] and antibodies
[24]. Silk also increases the stability of drugs and biomacromolecules
[25–27].
Protein HIV entry inhibitors are particularly valuable as potential
microbicides, both because of their high potency and because they are
not generally used in antiretroviral treatment and therefore would not
be expected to promote viral escape. These proteins include broadly
neutralizing antibodies (bnAbs) as well as the proteins 5P12-RANTES
(5P12R) and griffithsin, all of which are highly potent (sub-nM effec-
tiveness in vitro), and with a range of properties that are consistent with
vaginal and rectal administration [28–31]. BnAbs have been effective in
non-human primates and are currently in clinical trials as intravenous
prevention agents [6,32,33] and have been incorporated into vaginal
rings [34]. 5P12-RANTES a CCR5-binding protein which is derived
from the human chemokine RANTES [35] is non-inflammatory, able to
be made in clinical quantities, and is stable in both vaginal and rectal
lavage [29,36–38] and is being prepared for use in clinical trials.
Recently, we showed that silk discs could stabilize multiple HIV
entry inhibitors such as 5P12-RANTES for over a year at 50 °C, and that
silk discs could mediate the extended release of small amounts of
griffithsin for a month [39]. Our goal has been to develop silk for the
sustained release of inhibitory amounts of several microbicidal candi-
date proteins, including bnAbs and 5P12-RANTES for use as vaginal
inserts. Here we present the use of silk fibroin to mediate the sustained
release of a model antibody (IgG1) and of 5P12-RANTES. We show that
silk inserts can be loaded with substantial amounts of inhibitor, and
that the protein is released over the course of a month. Ex vivo studies in
blood and colorectal tissue, using released 5P12-RANTES, showed in-
hibition of HIV infection, demonstrating the feasibility of silk as a
sustained release delivery vehicle for HIV microbicides.
2. Materials and methods
2.1. Materials
Purified murine IgG1 monoclonal antibody was provided by Sanofi
Genzyme Corporation (Framingham, MA). Sodium chloride (NaCl),
disodium hydrogen phosphate dihydrate (Na2HPO4), 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES), lithium bromide
(LiBr), sodium carbonate (Na2CO3) and methanol (MeOH) were pur-
chased from Sigma Aldrich (St. Louis, MO). Phosphate buffered saline
(PBS) was obtained from Gibco™ (Life Technologies, Carlsbad, CA).
15N-isotopically labelled ammonium chloride (15NH4Cl) was purchased
from Cambridge Isotopes Lab (Tewksbury, MA).
2.2. Production of the 5P12-RANTES protein inhibitor
The protein 5P12-RANTES was produced recombinantly as de-
scribed previously [40,41]. Briefly, the gene encoding 5P12-RANTES
was subcloned into the pET32a expression vector, with N-terminal His6
and Thioredoxin fusion tags. The vector plasmid was transformed into
BL21 (DE3) E. coli cells (Novagen) and cultured in M9 media with
15NH4Cl as the sole nitrogen source. Protein overexpression was in-
duced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to
1mM concentration and incubated with shaking at 22 °C for 2 h, fol-
lowed by centrifugal harvest of cells. The bacterial pellets were re-
suspended in lysis buffer (8.0M Urea, 500mM NaCl, 10mM sodium
phosphate, pH 7.8) and cell membranes disrupted by homogenization
(Avestin®). After lysate centrifugation (27,000×g) for 1 h, supernatants
were collected and target protein purified using pre-packed Nickel
(Ni2+)-charged HiTrap® IMAC Sepharose FF columns (GE Healthcare
Life Sciences), followed by refolding using modified conditions identi-
fied from the FoldIt™ Screen (Hampton Research, Aliso Viejo, CA).
During subsequent dialysis, enterokinase was added to the protein to
cleave the N-terminal fusion tag [41]. The 5P12-RANTES protein was
further purified by reversed-phase HPLC (RP-HPLC) using a C4 column
(GraceVydac, Hesperia, CA), lyophilized and stored as powder until
use. Protein purity and integrity were verified by SDS-PAGE and by
1He15N heteronuclear single quantum coherence (HSQC) spectroscopy.
Protein concentrations in solution were determined from sequence-
based calculated molar extinction coefficients at 280 nm (http://web.
expasy.org/protparam). To fully cyclize the N-terminal glutamine re-
sidue (which spontaneously cyclizes in solution to form a pyr-
oglutamate moiety) of 5P12-RANTES, the protein was prepared at>
1mM concentration in 20mM sodium phosphate buffer, pH 2.5, and
incubated at 37 °C for at least 120 h [41], and completion of cyclization
was verified by NMR (1He15N HSQC spectra, data not shown).
2.3. Lyophilization of antibody
Antibody solutions were formulated in 0.02M histidine buffer
(pH 6.0) with 0.5% (w/v) sucrose at a 5mg/mL concentration. To ob-
tain powder IgG1, antibody solutions were lyophilized in a LyoStarII
tray freeze dryer (FTS Systems, Stone Ridge, NY) as previously de-
scribed [24]. Samples were frozen to −45 °C and held for 8 h. Primary
drying was performed at −20 °C, 100mTorr for 40 h, followed by
secondary drying at 35 °C, 100mTorr for 11 h. Lyophilized IgG1 sam-
ples were stored at 4 °C until use.
2.4. Silk fibroin isolation
Silk fibroin was isolated from B. mori cocoons as previously de-
scribed [7]. Briefly, cocoons were cut into approximately 1 cm2 pieces
and degummed by boiling in 0.02M Na2CO3 for 30min (30MB). Ob-
tained fibers were rinsed thoroughly in deionized water to remove
sericin proteins and air-dried overnight. Following overnight air-
drying, silk fibroin fibers were dissolved of 9.3M lithium bromide (1 g
in 4mL) for 4 h at 60 °C, then the solution was dialyzed (3.4 kDa
MWCO, Thermo Fisher Scientific, Waltham, MA) against ultrapure
water at room temperature for 3 days to remove LiBr. The resulting silk
solution (~7%) was centrifuged to remove residual debris and stored at
4 °C until use in production of IgG1-loaded devices. The silk solution
used in production of 5P12-RANTES discs underwent the additional
step of sterilization by autoclave and the resultant (~5.4% wt./vol.)
solution was stored at 4 °C until use.
2.5. Preparation of silk discs
Six percent, silk solution was used to prepare three types of discs;
methanol treated (MT), water vapor annealed (WVA) and silk coated
(SC). One millilitre silk solution was placed in 24-well plates and
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lyophilized to form blank silk discs, which were then soaked in 1mL of
80% MeOH for an hour to reduce solubility. Insoluble discs were then
soaked into 1mL of IgG1 aqueous solution (2.5 mg/mL) for 3 days and
then air-dried to obtain IgG1 loaded MT discs. To obtainWVA discs, IgG1
was weighed (2.5 and 5mg) and dissolved in silk solution and then
1mL of the mixture was placed in 24-well plates and lyophilized. The
resulting discs were water vapor annealed [42] for 24 h at room tem-
perature to induce crystalline structure. Some WVA discs were then dip
coated with 10 layers of silk to form SC discs.
Solutions of 5P12-RANTES (159 μg) were prepared in 20mM HEPES
buffer (pH 8.0) with or without 150mM NaCl. The protein solutions
were then combined with the aqueous silk solution to produce mixtures
containing a final concentration of 20 μM 5P12-RANTES, 1.5% or 2%
silk, and either 80mM NaCl or no Salt. Sets of controls were prepared
using ‘blank’ solutions containing only the HEPES buffer (and no 5P12-
RANTES) that were combined with silk to create discs with the desired
silk percentage and salt content. Sets of 1.0mL solution aliquots were
pipetted into sterile 24-well plates (with 1.7 cm well dia-
meter=~2.3 cm2 bottom surface area), frozen and lyophilized. Silk
discs were then prepared for sustained release by water vapor annealing
(WVA) at 37 °C with ≥75% relative humidity (RH) for various amounts
of time [42]. Trays of discs were then transferred to a 37 °C forced-air
incubator to allow the discs to dry, and were then stored in room-
temperature desiccators until use (or else were stored in a 50 °C forced-
air incubator for 1month prior to commencement of drug release ex-
periments). All stock solutions used in the creation of the 5P12-
RANTES/silk discs were assayed for endotoxin levels using the Tox-
inSensor Gel Clot Endotoxin Assay Kit (Genscript, Piscataway, NJ) and
showed< 0.25 EU/mL.
2.6. Characterization of silk discs
All discs were washed in PBS to remove free IgG1 and PBS was
analyzed to calculate the antibody loading in WVA and SC silk discs.
MT disc antibody loading was calculated based on the IgG1 con-
centration left in the loading solution. IgG1 was quantified chromato-
graphically, using a 1200 series HPLC (Agilent Technologies, Santa
Clara, CA) and a protein G ID cartridge (Applied Biosystems, Carlsbad,
CA) [24,27]. The binding mobile phase was 0.01M sodium phosphate,
0.15M sodium chloride, pH 7.3 and the elution buffer was 0.012M
hydrochloric acid, 0.15M sodium chloride, pH 2.0 with a flow rate of
1.5 mL/min. Column temperature was kept at 5 °C during the analysis
and the detection wavelength was 220 nm. Antibody concentrations
were calculated using a standard curve generated under the same
conditions.
Scanning Electron Microscopy (SEM) imaging was performed to
evaluate the morphology of the IgG1-containing silk discs using a Zeiss
EVO-10MA microscope (Zeiss, Oberkochen, Germany) at 5 kV accel-
erating voltage. Prior to imaging, the disc samples were coated with
∼10 nm gold using a SC7620 sputter coater (Quorum Technologies,
UK). Sets of silk discs for 5P12-RANTES release experiments were
sputter-coated with ~20 nm gold using a Polaron SEM Coating Unit
E5000 (Bio-Rad Microscience Ltd.) and SEM imaging was performed
using a Zeiss GeminiSEM-500 microscope with 3 kV accelerating vol-
tage.
The structural features and crystalline structure of the silk discs
were evaluated using Fourier Transform Infrared (FTIR) Spectroscopy
(JASCO FTIR 6200 spectrometer, Jasco, USA or a Bruker Vertex 70
spectrometer, Germany). The Amide I region (1605–1705 cm–1) of silk
fibroin structure was deconvoluted using OPUS 5.0 software (Bruker
Optics, USA) to determine β-sheet content as described previously [43].
Fourier Self Deconvolution was performed using a Lorentzian peak with
a half bandwidth of 27 cm−1 and a noise reduction factor of 0.3. One
Way ANOVA was performed for statistical analysis (p < .05) of the
FTIR results using IBM SPSS Statistics 22 Software (New York, USA).
2.7. In vitro release studies
2.7.1. Sustained release of IgG from silk discs
In vitro release studies were performed in 1mL PBS solution and
incubated at 37 °C. All of the PBS was collected at the sampling times
and replaced with fresh PBS. The amount of released IgG1 was quan-
tified using the HPLC method described in section 2.6. Blank disc
samples were also tested as a control group.
2.7.2. Sustained release of 5P12-RANTES from silk discs
The WVA-treated silk discs containing 5P12-RANTES (and silk-only
Fig. 1. SEM micrographs showing the porous structure of A) MeOH treated, 6% silk, blank discs (MT), B) Water vapor annealed (WVA), 6% silk, blank discs, C) WVA,
6% silk, IgG1 loaded discs; (D and E) WVA-treated, 2% silk, blank control disks with or without salt in the formulation; (F and G) 5P12-RANTES-loaded WVA-treated,
2% silk discs with or without salt. (Magnification= 100×, scale bar= 100 μm.)
Fig. 2. Structural properties of silk (SF) discs quantified by FTIR spectroscopy.
Percentage of the secondary structural content in all formulations for IgG-re-
lated (A) and 5P12-RANTES-related (5P12-R) (B) silk discs. (+) Salt formula-
tion indicates the presence of 80mM NaCl to the silk solution prior to lyophi-
lization. (All data represent mean ± SD for n=3, statistical significance
within groups has shown with *(p < .05)).
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control discs) were kept in sterile 24-well plates with 1.0 mL of PBS
added to each disc, and incubated at 37 °C with relative humidity
≥85%. To account for the initial “burst” effect often seen in drug re-
lease devices, the incubation solutions in each well were removed after
the first hour and fresh release media (PBS) was added to each disc.
Thereafter, time points were taken daily for the first week (7 days) and
every other day until Day 31. For each time point, the extracted volume
of release medium was measured and fresh solution (sterile PBS) was
added to continue the incubation. For the control set silk-only discs,
time points were taken in this same manner. The concentration of 5P12-
RANTES in each time point sample was quantified by ELISA. In brief,
time point samples were diluted with a given volume of coating buffer
(100mM sodium carbonate/bicarbonate, pH 9.5) and mixtures were
added 100 μL/well into a 96-well plate (Nunc, Thermo Fisher) and in-
cubated at 4 °C overnight. These solutions were subsequently removed,
and the plate wells were blocked with 3% BSA in Tris-Buffered Saline
(‘TBS’, 150mM NaCl in 20mM Tris, pH 7.6). After incubation and wash
steps, Biotinylated anti-Human RANTES monoclonal antibody (clone
VL-1, Thermo Scientific) was added to each well. Following incubation
and wash steps, horseradish peroxidase (HRP)-conjugated streptavidin
(R & D Systems) was added to each well. Subsequent to additional wash
steps, the substrate 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) (‘ABTS’, Thermo Scientific) was added to each well and signal
development was followed by measurement of absorbance at 405 nm.
Absorbance readings for ‘silk-only’ control disc time points were sub-
tracted from those measured in corresponding sets of 5P12-
RANTES–loaded silk discs. The standard curve in each assay was gen-
erated from a 20 μM 5P12-RANTES stock solution used to construct a
10-point concentration ladder with points ranging from 5 nM to
120 nM. Concentrations down to 10 nM could be readily detected in
this manner. Readings from the standard curve were fit to a four-
parameter logistic (4PL) curve and sample concentrations were calcu-
lated relative to this fitted curve, with time point concentration read-
ings being subsequently multiplied by the appropriate dilution factor.
2.8. IgG recovery from silk discs
Recovery of IgG1 from silk discs was evaluated at 4 °C, room tem-
perature (RT) and 37 °C for 4 weeks as a parameter of stability. After the
incubation time, non-treated discs were dissolved in water and re-
covered IgG1 was calculated in comparison to IgG1 solutions that were
incubated in the same storage conditions. IgG1 amounts in the samples
were quantified using IgG (Total) Mouse Uncoated ELISA Kit
(Invitrogen, Carlsbad, CA) as instructed by the manufacturer.
Denatured antibody (heated at 90 °C for 90min) was used to confirm
selectivity of ELISA method. IBM SPSS Statistics 22 Software was used
to perform One Way ANOVA and Tukey HSD post hoc tests for statistical
analysis (p < .05).
2.9. Cells and virus
TZM-bl cells [44–46] were grown in Dulbecco's Minimal Essential
Medium (DMEM) (Sigma-Aldrich, Inc., St. Louis, MO) containing 10%
fetal calf serum (FCS), 2 mM L-glutamine and antibiotics (100 U of pe-
nicillin/ml, 100 μg of streptomycin/ml) at 37 °C in an atmosphere
containing 5% CO2.
Full-length, replication and infection-competent proviral HIV-1
clone, pYU.2 [47,48] was provided by the NIH AIDS Research &
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Fig. 3. In vitro IgG1 release from silk discs. Released IgG1 amounts at each time point from A) MeOH treated discs, B) WVA discs, C) WVA 10× coated discs.
Cumulative IgG1 release percentage from E) MeOH treated discs, F) WVA discs, G) WVA 10× coated discs. Incubations in PBS were carried out directly at 37 °C for
32 days. The release medium (1.0 mL of PBS) was removed and replaced with fresh solution at every sampling time point. IgG1 concentrations in the release media
were determined for each time point by HPLC (as per the Methods section). Data presented are the mean ± SD of a triplicate (n= 3) of discs.
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Reference Reagent Program (http://www.aidsreagent.org/). The
plasmid was transfected into 293FT cells and passaged through acti-
vated peripheral blood mononuclear cells [49] for 11 days.
2.10. Patients and tissue explants
Surgically-resected specimens of colorectal tissue were collected at
St Mary's Hospital, Imperial College London, UK. All tissues were col-
lected after receiving signed informed consent from all patients and
under protocols approved by the Local Research Ethics Committee. All
patients were HIV negative. On arrival in the laboratory, resected tissue
was cut into 2–3mm3 explants comprising both epithelial and muscu-
laris mucosae as described previously [50]. Colorectal explants were
maintained with DMEM containing 10% fetal calf serum, 2mM L-glu-
tamine and antibiotics (100 U of penicillin/ml, 100 μg of streptomycin
/ml, 80 μg of gentamicin /ml) at 37 °C in an atmosphere containing 5%
CO2.
2.11. HIV inhibition assays
HIV Inhibition assays were performed using a standardized amount
of virus culture supernatant normalized for infectivity. Cells or tissue
explants were incubated with silk supernatant for 1 h at 37 °C before
addition of virus. For assays in TZM-bl cells, virus was left for 48 h.
Alternatively, virus (103 TCID50) was added to tissue explants for 2 h
and then explants were washed 4 times with PBS before transferring
onto gelfoam rafts (Welbeck Pharmaceuticals, UK) as described pre-
viously [51]. On days 3, 7, 11 and 15, approximately 2/3 of the su-
pernatant was harvested and explants were re-fed with fresh media
without compound. The extent of virus replication was determined in
TZM-bl cells by luciferase quantification of cell lysates (Promega, Ma-
dison, WI) and in tissue explants by measuring the p24 antigen con-
centration in supernatants (HIV-1 p24 ELISA, Launch Diagnostics Ltd.,
UK), as described previously [50].
2.11.1. Statistical and mathematical analysis of HIV inhibition
IC50 values were calculated from sigmoid curve-fits (GraphPad
Prism). All IC50 data presented fulfill the criterion of R2 > 0.7.
3. Results and discussion
3.1. Formulation and characterization of IgG1 and 5P12-RANTES in silk
discs
The model antibody IgG was incorporated into a 6% silk solution in
three ways, as described in Methods. Methanol treated (MT) discs uti-
lized lyophilized silk discs that were then treated with methanol and
subsequently introduced to IgG1. Water vapor annealed (WVA) discs
were prepared by first mixing the silk solution with IgG1, followed by
lyophilization and annealing in a controlled humid environment.
Finally, silk coated (SC) discs were prepared as WVA discs then sub-
sequently coated with layers of soluble silk to minimize initial burst
release and to allow for sustained release. IgG1 loading in the silk discs
was calculated based on the IgG1 concentration in PBS used to rinse
away residual the free antibody, as measured by HPLC. Average anti-
body loadings were 1425.7 ± 47.7, 4941.8 ± 49.2 and
2477.5 ± 6.0 μg for MT, WVA and SC discs respectively. The highest
loading efficiency achieved with SC discs was 99.1 ± 0.2% of the
available antibody. WVA discs followed with 98.8 ± 1.0%, whereas
the loading efficiency for MT discs was 57.0 ± 1.9%.
Morphology of the silk discs was evaluated using SEM. Micrographs
(Fig. 1) show the porous structure of the silk discs prepared for IgG
release studies, where larger pores are present in the blank (no IgG1)
MT discs (Fig. 1A) compared to the blank WVA discs (Fig. 1B). The
smaller pore sizes of WVA discs were associated with the higher loading
rate due to the larger surface area [52]. The effects of antibody and
protein loading on porous structure were also investigated. Addition of
the IgG1 protein to Silk Fibroin prior to casting and WVA produced
discs with smaller average pore size (Fig. 1C) compared to that of the
blank discs.
FTIR analysis confirmed the insoluble structure of the IgG-related
silk disc formulations following methanol treatment or water vapor
annealing based on their crystallinity. All formulations had high crys-
talline structures where β-sheet fractions were between 33.9 ± 1.0 to
39.0 ± 0.2% (Fig. 2A). The data showed MT discs have a significantly
higher β-sheet ratio as methanol treatment induces the silk II structure,
whilst water vapor annealing induces silk I structure, which is an or-
ganized crystalline form of fibroin which then transforms into the β-
sheet structure of Silk II that makes the fibroin strong, tough, and re-
sistant to release [53–55]. However, the IgG1 loaded MT discs showed
similar β-sheet content to that of the WVA discs, which indicates that
the difference in crystalline structure of the discs is not a significant
factor in their release profiles.
In order to achieve sustained release of 5P12-RANTES from silk over
a 1-month time period, different formulations were explored, including
variation of parameters such as silk percentage, length of time used in
the WVA process, and the salt (NaCl) content in the formulation. For
20 μM 5P12-RANTES concentration in a 1.0 mL final volume (corre-
sponding to a total of 158.5 μg inhibitor loaded), it was experimentally
determined (Fig. 4) that reasonable 5P12-RANTES release profiles
could be achieved with a formulation consisting of 2% (wt./vol.) silk
and a WVA duration of 7 h. The morphology of these disks (with or
without 80mM NaCl in the final prepared disc) was examined using
SEM. The micrographs (Fig. 1) reveal a highly porous architecture for
the silk-only control disks, though inclusion of salt (with final in-silk
concentration of 80mM NaCl) resulted in smaller average pore size
(Fig. 1D vs. Fig. 1E). Inclusion of 5P12-RANTES protein in the silk discs
Fig. 4. Periodic (left) and cumulative (right) in vitro release of 5P12-RANTES from WVA-treated 2% (wt./vol.) silk discs. One set of silk discs was formulated with final
concentrations of 20 μM 5P12-RANTES and 80mM Salt (NaCl) (A–D, gray bars and circles) and another set with 20 μM 5P12-RANTES and no Salt (E–H, white bars and
circles). Incubations in PBS were carried out directly at 37 °C (A–B, E–F) for 31 days; or after a set of discs had first been incubated under arid conditions at 50 °C for
1 month (C–D, G–H) prior to addition of PBS and time point collection. The release medium (1.0 mL of PBS) was removed and replaced with fresh solution each day
for the first 7 days, and subsequently every other day until Day 31. 5P12-RANTES concentrations in the release media were determined for each time point by ELISA
(as per the Methods section). Data presented are the mean ± SD of a triplicate (n= 3) of discs.
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significantly altered their porous structure, causing the formation of
much larger pore size (Fig. 1F,G) and a certain ‘stringy’ appearance for
the formulation that included salt (80mM NaCl in the 1.0 mL formula
volume) (Fig. 1F). There were also visible differences in the gross
morphology (visible to the unaided human eye) of the discs: whereas
the 5P12-RANTES-containing silk discs with no salt maintained a
spongy and compressible form that could be readily lifted off the
bottom of its slot in the 24-well tray after WVA treatment and overnight
drying, the discs formulated with salt were much more brittle and fri-
able, having a more ‘feathered-needlelike’ form that could not be
readily removed from the bottom of the plastic well. Therefore, this
formulation (WVA treated, 2% silk, formulated with salt) would likely
need to be adjusted by increasing silk concentration or reducing salt for
practical use.
FT-IR analysis of secondary structural content was also performed
for the 5P12-RANTES-related silk discs and revealed significant β-sheet
content, ranging from 38.6 ± 0.2% to 40.9 ± 1.7% among all for-
mulations examined (Fig. 2B), consistent with the percentage β-sheet
content previously reported for SF of 1 or 2% (wt./vol.) that had been
WVA-treated at 37 °C and for the same duration employed here [42].
The percent β-sheet content observed here was thus largely invariant to
our inclusion of salt or 5P12-RANTES protein in the formulation, in-
dicating that differences in gross morphology and porous architecture
of the silk discs, as well as drug release profiles (Fig. 4), are not cor-
related with differences in secondary structural content of the SF in
these devices.
Fig. 6. Inhibitory potency of 5P12-RANTES released
at different time points from silk disks. TZM-bl cells
were pre-incubated with serial dilutions of super-
natants for 1 h prior to addition of virus, HIV-1
cYU.2. Luciferase expression (r.l.u. values) was de-
termined after 48 h and the extent of inhibition by
each drug was calculated. The percentage of inhibi-
tion was normalized relative to the r.l.u values ob-
tained for cells grown in the absence of virus (100%
inhibition) and for cells infected with virus in the
absence of drug (0% inhibition). Inhibition by su-
pernatants from control (open symbols) or 5P12-
RANTES-containing silk discs (filled symbols) har-
vested at days 7 ( , ), 21 ( , ) or 31 ( , )
and containing A: 5P12-RANTES released from 2%
silk, WVA discs formulated with 80mM NaCl, in-
cubated at 37 °C; B: Inhibition of 5P12-RANTES re-
leased from 2% silk, WVA discs formulated with
80mM NaCl, incubated at 50 °C for one month, then
stored at 37 °C; C: Inhibition of 5P12-RANTES re-
leased from 2% silk, WVA discs formulated with no
added salt, incubated at 37 °C, release at Day 7. Data
are the mean (± SD) of duplicates.
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3.2. In Vitro release studies
3.2.1. Sustained release of IgG from silk discs
Phosphate-buffered saline (PBS) was incubated with each disc at
37 °C for various amounts of time to determine the release rate. MT,
WVA and SC discs released 34.7 ± 0.46%, 10.4 ± 0.41%, and
2.1 ± 0.5% of the encapsulated IgG1 in the first 24 h and
95.6 ± 0.49%, 18.9 ± 0.01, 5.2 ± 0.03% at the end of the 29 days,
respectively (Fig. 3). The released IgG1 was significantly different for
all three formulations (p < .05), where MT discs had a burst release
and the highest release ratio in compliance with their large porous
structure. Smaller pores create a larger surface area and provide a more
controlled release from WVA discs [56]. SC discs released a smaller
portion of the total loaded antibody where 10 layers of silk coating
provided a sustained release profile without any burst. This showed that
altering the layers of the coating to increase or decrease the release rate
could modify release from the discs. Methanol treated discs were the
most able to quickly release IgG, showing 34.7 ± 0.46%
(494.3 ± 6.6 μg) release in 1 day, with more material released at day 3
(1147.5 ± 11.5 μg) and most released within a week (Fig. 3). With the
ability of releasing milligram levels of antibody, this formulation would
therefore be suitable for so-called “weekend release” in which a person
may be well protected for a few days but not for an extended period of
time. On the other hand, SC discs are able to release smaller portion of
the antibody over the course of a month with an average of 4.3 μg per
day, which can be used to provide a long-term maintenance dose.
3.2.2. Sustained release of 5P12-RANTES from silk discs
As noted in the IgG release studies, WVA mediates a combination of
traits in the silk disc to allow both a substantial burst of inhibitor re-
lease (to provide protection within minutes or hours of insertion), as
well as a continuous release of inhibitor over the course of days and
weeks. Therefore, silk discs prepared with 5P12-RANTES and WVA
treatment were tested under several conditions to determine their sta-
bility and release capability. While extended duration of the WVA
process results in a fully insoluble silk matrix with high β-sheet content,
this can hamper drug release from the matrix; inversely, insufficient
WVA processing can produce a silk scaffold that dissolves in aqueous
solution and is unable to mediate sustained drug release [42]. For a
formulation of 2% (wt./vol.) silk encapsulating 158.5 μg of 5P12-
RANTES in a 1.0 mL volume (20 μM final in-silk concentration of the
drug) a 7-hour WVA was determined to produce reasonable release
profiles of the drug into PBS at 37 °C (Fig. 4).
Given the disparity in pI (isoelectric point) values of the drug (5P12-
RANTES, pI ~9.5) and silk (pI ~4.5) [35,57], it was hypothesized that,
for near-neutral pH release medium (PBS, pH ~7.3), there might be a
significant electrostatic component to the interaction between silk and
5P12-RANTES. In light of this, two different formulations were
created—one containing a final 80mM concentration of NaCl, and one
with no salt. For the set of discs containing NaCl in the formulation
(Fig. 4A–B), the initial ‘burst’ time point (removed at T=1hour post-
addition of PBS to the dried device) contained approximately 99 μg,
corresponding to ~62% of the total amount of drug loaded, with a
cumulative 71% release after the first 24 h. After Day 7, a more linear
release rate was observed with an average of ~0.34 μg per day between
days 7 and 31, corresponding to maintenance of a ~43 nM concentra-
tion of inhibitor in the approximate 1mL fluid volume used in this
study, which is above the ex vivo IC50 of 5P12-RANTES measured in
PBMCs and colorectal tissue explants [39], and orders of magnitude
above the value in other in vitro tests [38,40]. After 31 days, a cumu-
lative total of 137.4 ± 11.9 μg of 5P12-RANTES had been released,
corresponding to 86.7 ± 7.5% of the total amount of drug initially
loaded into the device.
For the set of discs formulated without salt (Fig. 4E–F), the initial
(T=1 h) burst time point contained ~11.3 μg of inhibitor, corre-
sponding to ~7.2% of total drug loading, and a cumulative total 12.9%
released after the first 24 h. For comparison, between days 7 and 31, an
average of ~0.41 μg per day was released, corresponding to main-
tenance of a ~51 nM inhibitor concentration in a 1mL volume. At the
end of 31 days, a cumulative total 52 ± 5.9 μg or, 32.8 ± 3.7% of the
total amount of drug loaded was released. Overall, we see that inclusion
of NaCl in the formulation served to increase the initial ‘burst’ effect
release of drug from the silk discs but did not significantly alter the rate
of release between days 7 and 31, with the ‘no salt’ formulation having
a just slightly higher release rate during that phase. Rather than having
noticeable effect on the putative significant electrostatic contribution to
the interaction between silk and 5P12-RANTES, the impact of salt in-
cluded in the formulation may have merely served to alter the gross
morphology of the silk discs (see Section 3.1 above), creating greater
exposed surface area which, in turn, produced greater initial surface
escape of the drug from the device.
Additional sets of silk-5P12-RANTES discs were stored for one
month at 50 °C to simulate unrefrigerated sub-Saharan conditions, then
placed at 37 °C and PBS release media added. As described before,
1.0 mL of PBS was incubated with the discs at 37 °C and then removed
and replaced with fresh buffer at various time points. As shown in Fig. 4
(parts C–D and G–H), comparable release amounts and profiles were
observed for these sets of discs as for the identically-formulated discs
that were only ever exposed to temperatures of 37 °C or less, demon-
strating that 1month of exposure to elevated temperature does not
significantly alter the release kinetics of 5P12-RANTES from the silk.
For all formulations and temperature exposure conditions tested, the
WVA-treated silk discs maintained their general structure and appear-
ance while gradually releasing 5P12-RANTES for 31 days. However, it
should be noted that discs lacking salt in the formulation are likely to be
more mechanically robust and better withstand handling and usage
Fig. 7. HIV Inhibitory function of 5P12-RANTES-
containing supernatants in colorectal explants.
Colorectal explants were treated for 1 h in the pre-
sence or absence of supernatants at a single dilution
(3/5) prior to viral challenge with HIV-1 cYU.2.
After 2 h of exposure to virus, explants were trans-
ferred on gelfoam rafts and cultured for 15 days. The
levels of p24 in the harvested supernatants were
quantified by ELISA and the extent of inhibition was
calculated. The level of infection was normalized
relative to the p24 values obtained for explants not
exposed to virus (100% inhibition) and for explants
infected with virus in the absence of compound (0%
inhibition). Supernatants harvested at different time
points from control (open symbols) or 5P12-
RANTES-containing (filled symbols) 2% silk, WVA
discs formulated with 80mM NaCl incubated at 37 °C ( , ); incubated at 50 °C for one month, then stored at 37 °C ( , ); or from 2% silk, WVA discs formulated
with no added salt, incubated at 37 °C ( , ). Data shown are the mean (± SD) of triplicates at day 15.
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within the human body.
Overall, these results show that several silk formulations could be
suitable for use as insertable anti-HIV microbicides, with perhaps the
best combination of traits being observed in WVA-prepared discs. These
show high release short term and significant release longer term of both
the model antibody IgG and the HIV inhibitor 5P12-RANTES. Tuning
the formulation with percentage of silk and amount of time for WVA
may lead to more optimal results. The use of layering silk onto the discs
to attenuate the initial burst in combination with WVA may also ulti-
mately provide an optimal amount of short and long-term release. In
our studies, substantially more protein was used in the IgG studies,
demonstrating that silk can be loaded with the large amounts of protein
that would be required for human studies. However, due to its potent
inhibitory capability, 5P12-RANTES amounts (limited by quantity
available) were consistent with full in vitro inhibition and are ap-
proaching the amount needed for in vivo macaque studies (preliminary
work ongoing).
3.3. IgG1 recovery from silk discs
In general silk stabilizes sensitive materials such as RNA, blood
components and proteins, which remain functional even after extended
periods at high temperatures [26,39,58,59]. IgG1 was incubated at 4 °C,
room temperature (RT) and 37 °C for 4 weeks, both in solution form and
in a rapid-dissolve silk disc to evaluate the stabilization effect of silk.
The discs were dissolved in water on the day of preparation (D0)
(controls) to test the immediate recovery of IgG1, and 87.0 ± 3.9% of
the IgG1 was recovered. This was used as the baseline level of IgG1 in
the subsequent recovery calculations. In addition, the recovery of pro-
tein tends to decrease with time upon exposure of the silk matrix to heat
and humidity resulting in silk crystallization, thus, making extraction of
the IgG1 more difficult as the discs lose dissolution in water by 30 days
[42].
After 3 days at 37 °C, IgG1 in the extract had 62.8 ± 15.2% of the
IgG1 was recovered from the silk discs. The percent recovered IgG1 was
higher in the silk discs than in solution at all temperatures tested for
28 days (Fig. 5) despite the losses in the extraction process due to the
changes in the silk matrix with time. The recovered IgG1 loss in solu-
tion form was significant after 21 days at 4 °C and 37 °C (p < .05),
while no significant recovery loss was observed in silk discs except with
the 37 °C storage.
3.4. Functional protein released from silk discs
5P12-RANTES is functional when released from silk discs. 5P12-
RANTES released from WVA-treated, salt containing discs, that had
been incubated at 37 °C (i,e, from Fig. 4A and B), was tested against
replication competent HIV as shown in Fig. 6A. First, several time
points were incubated in TZM-bl cells at various levels of dilution and
then challenged with HIV strain cYU.2. Significant inhibition was ob-
served for time points from 7, 21, and 31 days, including 100% in-
hibition up to three weeks for the undiluted sample. As shown in
Fig. 6B, significant inhibition over the silk-only control was also ob-
served for inhibitor released from discs described in Fig. 4C and D, that
had first been incubated at 50 °C then tested for sustained release at
37 °C. In this case, near-full inhibition was observed for the 7-day
sample, with less inhibition at later time points. Finally, silk discs for-
mulated with lower salt content (from Fig. 4 E and 4F) were fully in-
hibitory even when diluted 100-fold at the 7-day time point (Fig. 6C).
These discs were not tested past 7 days because our release studies
showed essentially equivalent amounts of inhibitor released after one
week for the discs formulated with and without salt. Further, osmo-
larity plays a large role in insertable formulations; particularly those
that may be used in the digestive tract, so experiments proceeded lar-
gely with the silk discs containing moderate salt amounts [60–62].
Functionality of the released 5P12-RANTES was also tested against
human colorectal explant tissue. As shown in Fig. 7, for all discs tested,
supernatants harvested at day 7 were able to fully inhibit HIV-1 YU.2;
and despite progressive loss of inhibition observed, supernatants har-
vested at day 31 still reach inhibitory levels above the IC50. As noted
above, discs formulated without salt were inhibitory, but performed
less well, possibly due to low osmolarity.
Overall, this work shows that silk discs can encapsulate and release
IgG, a model antibody that is expected to act similarly to broadly
neutralizing antibodies against HIV. We also demonstrate that silk in-
serts can reliably release μg amounts of 5P12-RANTES daily over the
course of weeks into PBS. Our current inserts are relatively small (1mL)
and loaded with 0.159mg protein, resulting in concentrations that
significantly larger than the IC50 of the protein. This level and even
higher amounts are generally deemed necessary for in vivo use. These
discs, loaded with higher protein amounts (experiments ongoing), are
appropriate for macaque testing and would be scaled up for use in
humans. Successful sustained release results are seen for discs that have
been pre-incubated for 1month at 50 °C, demonstrating that these silk
discs would not require refrigeration in developing countries such as
those in sub-Saharan Africa, even if they are stored first for weeks in a
warehouse or kept in an automobile.
The silk inserts, therefore, show several of the properties that are
critical for use as HIV microbicides, such as the ability to use these
without medical intervention, the stability after storage at high tem-
peratures, and to be protective immediately upon insertion and po-
tentially for several weeks. While this demonstrates the core of what is
required for a vaginal microbicide, two key additional issues must be
addressed. First, it has been repeatedly demonstrated that user ac-
ceptability is critically important, as clinical trials of effective materials
have failed due to poor compliance, particularly among young women
and adolescents [5]. Silk has some advantages in this regard, as it is a
natural silk product that can be marketed as having properties asso-
ciated with silk such as smoothness and even luxury. Further, silk can
be formulated into a variety of shapes and colors, and the basic disc can
be shaped by the user prior to insertion which is expected to be at-
tractive to young women. A second major obstacle to a long-acting silk
insert is the necessity of remaining in place in the cervico-vaginal area
throughout menses and coitus. While studies are ongoing with maca-
ques to determine in vivo distribution from silk in short time frames, the
current formulation must clearly evolve to include muco-adhesives that
would allow for success in placement for longer time periods [63–65].
Overall, we demonstrate that silk can be used to encapsulate anti-
bodies and a potent anti-HIV protein, 5P12-RANTES, formulated to
release inhibitory amounts of the protein over the course of weeks. This
demonstrates that silk/protein combinations are uniquely capable of
meeting numerous requirements for preventing HIV transmission in the
real world situations where effectiveness and user acceptability are
recognized as critical factors in successful outcomes. Here, the material
can be formulated in either a quick dissolving format or in a sustained
release format. Current protein inhibitors are used, as opposed to using
small molecule drugs that are currently in the treatment regimen (and
which may encourage HIV mutation making the small molecules less
effective). Further, the material can be stored without refrigeration for
improved distribution to users, can be easily inserted by the user; the
silk insert can be prepared in a variety of shapes and even colors, and
the material is a natural and safe product, leading to high user ac-
ceptability and demand. This unique combination of effectiveness over
days or weeks and attractive formulations supports the assertion that
silk/protein inserts could be a valuable component in an arsenal of HIV
prevention choices.
4. Conclusions
We describe the formulation and characterization of silk discs that
provide sustained release of two proteins that are relevant for HIV
prevention. Using IgG as a model for broadly neutralizing antibodies,
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we demonstrate several formulations with silk and show release of
protein up to a month. We further show that the potent HIV entry in-
hibitor 5P12-RANTES can be incorporated into silk discs, release pro-
tein for up to 31 days, and that the released protein can inhibit HIV
infection in both blood and in human colorectal tissue. Therefore, silk is
a highly promising material for use as a sustained release delivery ve-
hicle in an HIV microbicide.
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